Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 10;3:15056. doi: 10.1038/mtm.2015.56

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Effect of AAV-ET3 gene therapy on preexisting anti-ET3 immunity. (a) Individual anti-ET3 ELISA titers for (closed shapes) the naive hemophilia A mice preimmunized with ET3 and treated with 4 × 10¹² vp/kg of AAV8-HLP-ET3 vector and (open shapes) the preimmunized controls. (b) Anti-ET3 Bethesda titers in (closed shapes) the naive hemophilia A mice preimmunized with ET3 and treated with 4 × 10¹² vp/kg of AAV8-HLP-ET3 vector and (open shapes) the preimmunized controls. AAV, adeno-associated virus; BU, Bethesda units; HLP, hybrid liver-specific promoter.